Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2023-01-01 DOI:10.1016/j.retram.2022.103363

Azin Alizadehasl , Nashmil Ghadimi , Hossein Hosseinifard , Kamran Roudini , Amir Hossein Emami , Ardeshir Ghavamzadeh , Davood khoda-Amorzideh

{"title":"Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis","authors":"Azin Alizadehasl , Nashmil Ghadimi , Hossein Hosseinifard , Kamran Roudini , Amir Hossein Emami , Ardeshir Ghavamzadeh , Davood khoda-Amorzideh","doi":"10.1016/j.retram.2022.103363","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span>Hematopoietic Stem Cell Transplantation (HSCT), is performed to treat many </span>malignancies such as autologous or allogenic. Despite the success of this method in treating patients, - sometimes some HSCT recipients face problems such as cardiovascular complications. Therefore, this </span>systematic review and meta-analysis aimed to evaluate the prevalence of cardiovascular complications in post-transplant patients.</p></div><div><h3>Method</h3><p><span>In order to review the published studies, we examined PubMed, MEDLINE, Cochrane Library, </span>Scopus, and web of science databases from the beginning to the end of January 2022, and we used tools by the Newcastle–Ottawa Scale to evaluate the quality of the studies.</p></div><div><h3>Result</h3><p><span><span>In this study, 37 articles were included in the meta-analysis and 30,957 patients were examined. Also, the mean age of patients was 35.37 years. Based on the results of the meta-analysis, the prevalence of cardiovascular disease (CVD), was 16.84%. In addition, other complications related to CVD which include Arrhythmias, Congestive Heart Failure (CHF), Hypertension, stroke, and mortality were examined </span>in patients who had hematopoietic stem cell transplantation and the resulting amounts were 3.91%, 3.66, 17.71, 0.22%, and 1.53%, respectively</span><strong>.</strong></p></div><div><h3>Conclusion</h3><p>This study showed that the prevalence of cardiovascular disease after hematopoietic stem cell transplantation is high and needs special attention.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 1","pages":"Article 103363"},"PeriodicalIF":3.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318622000319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hematopoietic Stem Cell Transplantation (HSCT), is performed to treat many malignancies such as autologous or allogenic. Despite the success of this method in treating patients, - sometimes some HSCT recipients face problems such as cardiovascular complications. Therefore, this systematic review and meta-analysis aimed to evaluate the prevalence of cardiovascular complications in post-transplant patients.

Method

In order to review the published studies, we examined PubMed, MEDLINE, Cochrane Library, Scopus, and web of science databases from the beginning to the end of January 2022, and we used tools by the Newcastle–Ottawa Scale to evaluate the quality of the studies.

Result

In this study, 37 articles were included in the meta-analysis and 30,957 patients were examined. Also, the mean age of patients was 35.37 years. Based on the results of the meta-analysis, the prevalence of cardiovascular disease (CVD), was 16.84%. In addition, other complications related to CVD which include Arrhythmias, Congestive Heart Failure (CHF), Hypertension, stroke, and mortality were examined in patients who had hematopoietic stem cell transplantation and the resulting amounts were 3.91%, 3.66, 17.71, 0.22%, and 1.53%, respectively.

Conclusion

This study showed that the prevalence of cardiovascular disease after hematopoietic stem cell transplantation is high and needs special attention.

查看原文本刊更多论文

造血干细胞移植后心血管疾病:系统回顾和荟萃分析

背景造血干细胞移植（HSCT）用于治疗许多恶性肿瘤，如自体或同种异体。尽管这种方法在治疗患者方面取得了成功，但有时一些HSCT接受者会面临心血管并发症等问题。因此，本系统综述和荟萃分析旨在评估移植后患者心血管并发症的发生率。方法为了回顾已发表的研究，我们从2022年1月初到1月底检查了PubMed、MEDLINE、Cochrane Library、Scopus和web of science数据库，并使用纽卡斯尔-渥太华量表的工具来评估研究的质量。结果在本研究中，37篇文章被纳入荟萃分析，30957名患者接受了检查。此外，患者的平均年龄为35.37岁。根据荟萃分析结果，心血管疾病（CVD）的患病率为16.84%。此外，在接受造血干细胞移植的患者中，检查了与CVD相关的其他并发症，包括心律失常、充血性心力衰竭（CHF）、高血压、中风和死亡率，结果分别为3.91%、3.66、17.71、0.22%和1.53%，分别地结论造血干细胞移植后心血管疾病的发生率较高，需要特别关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.